Cover Image
Market Research Report

Global Metastatic Cancer Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024

Published by KuicK Research Product code 616601
Published Content info 330 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Metastatic Cancer Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024
Published: March 20, 2018 Content info: 330 Pages
Description

Report Highlights:

  • Drug Patent, Availability, Price & Dosage Analysis
  • Market Analysis of Metastatic Cancer
  • Management Approaches for Metastatic Cancer by Type
  • Global Cancer Metastases Clinical Pipeline Overview: 66 Drugs
  • Marketed Cancer Metastases Drugs Clinical Insight: 14 Drugs
  • Future Perspective of Metastatic Cancer Market

Cancer is a complex disease which results in uncontrolled cell growth in any region or organ of the body. Cancer is segmented into different stages depending upon the spread of tumor cells within the body. Primary stages of cancer involve the uncontrolled growth of cancer cells within a confined region or organ of a body. In further stages, cancer either returns to other organs after being treated in one organ or cancer cells metastasizes or moves from one organ to other. Such conditions are termed as metastatic cancers. For instance, re-occurrence of Breast cancer or metastasis of Breast Cancer to lungs is not called Lung cancer but is known and treated as stage-IV breast cancer.

In 2017, 600920 deaths occurred due to metastatic cancers in US alone. In developing countries, the death rates due to metastatic cancers are even higher due to lack of early stage diagnosis of cancer. Earlier, lesser therapies were available for increasing the period of progression free survival of patients with metastatic cancers and the metastatic cancer market was not clearly differentiated from overall cancer therapy market.

However, a clear segment of Metastatic Cancer Therapy Market has emerged in last few years with the arrival of products like Provenge which is vaccine specifically indicated for metastatic Prostate cancer. Additionally, several commercially available immunotherapeutics were also included in this segment of the market such as Avastin, Herceptin, and Denosumab along with targeted drugs like Afatinib, Gefitinib, and Erlotinib etc. for metastatic breast and lung cancer respectively. Metastatic cancer therapy market is further segmented into each type of metastatic cancer such as lung cancer, breast cancer, prostate cancer, brain tumor and several others which are the most common types of cancers globally indicating a large target patient base of this segment of the market.

High medical needs of patients with metastatic cancers have fuelled global metastatic cancer therapy market at an impressive average 8 CAGR calculated on the basis of the market growth for each indication. Currently the global metastatic cancer therapy market is well flourished with more than 10 unique products including advance cancer therapies like targeted therapy, cancer vaccines, immunotherapies and some modern versions of chemotherapies like Jevtana. Additionally, more than 60 products are currently in the later phases of clinical pipeline with almost 60% in phase-III and 37% in phase-I & II of the clinical trial.

The global metastatic cancer therapy market is growing significantly with increasing sales of some major drugs like an Eli Lilly product Alimta with average sales of US$ 2.5 Billion per year; Prolia by Amgen having US$ 1.9 Billion sales in just 9 months of 2017; Products of Roche Avastin and Herceptin are the top selling drugs of this segment having sales of US$ 5.2 Billion & US$ 5.4 Billion respectively in the year 2017.

Involvement of several large scale pharmaceutical countries clearly suggests that global metastatic cancer therapy market is a highly recognized segment of the cancer therapy market which has attracted the private and public sectors for huge investments and funding resulting in high market size of the segment. Additionally, successive collaborations between large scale and small scale biotech firms, academia and pharmaceutical companies have resulted into entrance of a wide range of unique products in metastatic cancer therapy market.

The global metastatic cancer therapy market can be segmented by regions into dominant areas like North America, Japan and South Korea with wide availability of a range of unique products in the market. On the other hand, highly populated regions like China and India have an opportunistic market for metastatic cancer therapies as the early stage cancer diagnostic market has recently emerged, thus there is a presence of large population living with later stages of cancer. Moreover, India is already developing vaccines and immunotherapies for metastatic cancer to decrease the mortality rates in the country which will further boost the market by products.

KuicK Research has analyzed the current and future global metastatic cancer therapy market by studying data related to sales of the products present in this market, prevalence and availability based target-patients in different regions of the world to provide an accurate forecast of the market. The report also includes price, dosage and efficiency analysis of all the products which aids in suggesting the future consumer acceptance and major contributors of the market.

Table of Contents

Table of Contents

1. Cancer Metastasis: New Perspectives of Old Problem

  • 1.1 Overview to Cancer
    • 1.1.1 Process of Metastatic Cancer
    • 1.1.2 Risk Factors Involved for the Metastasis of Cancer
  • 1.2 Genes Involved in Metastasis of Cancer

2. Metastatic Lung Cancer

  • 2.1 Introduction
  • 2.2 Management Approaches for Metastatic Lung Cancer
  • 2.3 Advancements in the Treatment of Metastatic Lung Cancer

3. Metastatic Bone Cancer

  • 3.1 Introduction
  • 3.2 Management Approaches of Metastatic Bone Cancer

4. Metastatic Breast Cancer

  • 4.1 Overview
  • 4.2 Management Methods for Metastatic Breast Cancer
  • 4.3 Ongoing Advancements in Metastatic Breast Cancer Treatment

5. Metastatic Liver Cancer

  • 5.1 Introduction
  • 5.2 Management Approaches of Metastatic Liver Cancer

6. Metastatic Brain Cancer

  • 6.1 Outline
  • 6.2 Management Methods for Metastatic Brain Tumor
  • 6.3 Developments in Metastatic Brain Tumors

7. Metastatic Prostate Cancer

  • 7.1 Introduction
  • 7.2 Management of Metastatic Prostate Cancer
  • 7.3 Recent Advances in Metastatic Prostate Cancer Treatment

8. Process of Metastasis in Other Different Types of Cancers

  • 8.1 Ovarian Cancer
  • 8.2 Thyroid Cancer
  • 8.3 Pancreatic Cancer

9. Patent, Availability, Price & Dosage Analysis of Metastatic Lung Cancer Therapeutics

  • 9.1 Targeted Drugs
    • 9.1.1 Erlotinib (Tarceva)
    • 9.1.2 Gefitinib (Iressa)
    • 9.1.3 Afatinib (Gilotrif)
  • 9.2 Chemotherapy Drugs
    • 9.2.1 Cisplatin
    • 9.2.2 Topotecan (Hycamtin)
    • 9.2.3 Pemetrexed (Alimta)

10. Patent, Availability, Price & Dosage Analysis of Metastatic Bone Cancer Therapeutics

  • 10.1 Denosumab
  • 10.2 Radium 223
  • 10.3 Zoledronic acid

11. Patent, Availability, Price & Dosage Analysis of Metastatic Breast Cancer Therapeutics

  • 11.1 Chemotherapy Drugs
    • 11.1.1 Capecitabine
    • 11.1.2 Eribulin (Halaven)
    • 11.1.3 Ixabepilone (Ixempra)
  • 11.2 Targeted Therapy Drugs
    • 11.2.1 Avastin (Bevacizumab)
    • 11.2.2 Herceptin

12. Patent, Availability, Price & Dosage Analysis of Metastatic Liver Cancer Therapeutics

  • 12.1 Sorafenib (Nexavar)
  • 12.2 Melphalan (Alkeran)

13. Patent, Availability, Price & Dosage Analysis of Metastatic Prostate Cancer Therapeutics

  • 13.1 Taxotere (Docetaxel)
  • 13.2 Jevtana (Cabazitaxel)
  • 13.3 Provenge (Sipuleucel-T)

14. Market Analysis of Metastatic Cancer

  • 14.1 Current Market Growth of Metastatic Cancer by its Types
  • 14.2 Global Sales of Metastatic Cancers Drugs

15. Market Dynamics of Metastatic Cancer

  • 15.1 Favorable Parameters
  • 15.2 Challenges

16. Future Perspective of Metastatic Cancer Market

17. Global Cancer Metastases Clinical Pipeline Overview

18. Global Cancer Metastases Clinical Pipeline by Company, Indication & Phase

  • 18.1 Research
  • 18.2 Preclinical
  • 18.3 Clinical
  • 18.4 Phase-0
  • 18.5 Phase-I
  • 18.6 Phase-I/II
  • 18.7 Phase-II
  • 18.8 Phase-III
  • 18.9 Preregistration

19. Marketed Cancer Metastases Drugs Clinical Insight

  • 19.1 Denosumab (PRALIA, Prolia, Ranmark & Xgeva)
  • 19.2 Radium-223 Chloride (Alpharadin & Xofigo)
  • 19.3 Zoledronic Acid (Aclasta, Reclast & Zometa)
  • 19.4 Pamidronic Acid (Aminomux, Aredia & Panorin)
  • 19.5 Clodronic Acid (Ascredar, Bonefos, Bonephos, Clasteon, Clastoban, Climaclod, Clodeosten, Clodron, Clodron beta, Clody, Difosfonal, Dolkin, Hemocalcin, Lodronat, Loron, Lytos, Mebonat, Moticlod, Nikclod, Ossiten, Ostac, Osteonorm, Osteostab & Sindronat)
  • 19.6 Ibandronic Acid (Bondronat, Boniva & Bonviva)
  • 19.7 Thiotepa (Tepadina & Thioplex)
  • 19.8 Miltefosine (Impavido, Miltefosin & Miltex)
  • 19.9 Irinotecan-Eluting Beads (DEBIRI & PARAGON Bead)
  • 19.10 Melphalan Drug Delivery System (Delcath Hepatic CHEMOSAT Delivery System for Melphalan & Melblez Kit)
  • 19.11 Ethiodised Oil (Lipiodol)
  • 19.12 Zoledronic Acid - Sagent Pharmaceuticals
  • 19.13 Tc 99m Besilesomab (Scintimun)
  • 19.14 Mopidamol (Rapenton)

20. Competitive Landscape

  • 20.1 Allergan
  • 20.2 Amgen
  • 20.3 Biocompatibles International
  • 20.4 Boehringer Ingelheim Pharma
  • 20.5 Celsion Corporation
  • 20.6 DexTech Medical
  • 20.7 Immune Pharmaceuticals
  • 20.8 GlaxoSmithKline
  • 20.9 Hospira
  • 20.10 Insmed
  • 20.11 Novartis
  • 20.12 Pfizer
  • 20.13 Roche

List of Figures

  • Figure 1-1: Reasons for the Development of Cancer Cases (%)
  • Figure 1-2: Process Involved in the Metastasis of Cancer
  • Figure 1-3: Classes of Genes Participating in Metastatic Process in Cancer
  • Figure 2-1: Diagnostic Methods for Metastatic Lung Cancer
  • Figure 3-1: Diagnostic Approaches for Metastatic Bone Cancer
  • Figure 4-1: Metastatic Breast Cancer Diagnostic Methods
  • Figure 5-1: Metastatic Liver Cancer Diagnostic Methods
  • Figure 5-2: Treatment Approaches for Metastatic Liver Cancer
  • Figure 6-1: Diagnostic Approaches to Brain Tumor
  • Figure 6-2: Treatment Methods for Metastatic Brain Tumor
  • Figure 7-1: Diagnostic Approaches for Metastatic Prostate Cancer
  • Figure 7-2: Treatment Methods for Metastatic Prostate Cancer
  • Figure 9-1: Tarceva - Patent Approval & Expiration Year for Advance Stage Lung Cancer
  • Figure 9-2: Tarceva - Available Concentrations (mg), 2018
  • Figure 9-3: Tarceva - Dosage Analysis & Dose Modifications (mg/Day), 2018
  • Figure 9-4: Tarceva - Increased Dosage by Condition (mg/Day), 2018
  • Figure 9-5: Tarceva - Price Analysis by Concentration (US$), 2018
  • Figure 9-6: Tarceva - Therapy Cost Analysis (US$/Patient), 2018
  • Figure 9-7: Gefitinib - Drug Patent Approval Year & Expiration Year for Lung Cancer
  • Figure 9-8: Gefitinib - Clinical Efficacy by Patients Undergoing Treatment (%), 2018
  • Figure 9-9: Gefitinib - Dosage Analysis (mg), 2018
  • Figure 9-10: Gefitinib - Available Concentrations (mg), 2018
  • Figure 9-11: Gefitinib - Therapy Cost Analysis (US$/Patient), 2018
  • Figure 9-12: Afatinib - Patent Approval & Expiration Year for the Treatment of Lung Cancer
  • Figure 9-13: Afatinib - Available Concentrations (mg), 2018
  • Figure 9-14: Afatinib - Therapy Cost Analysis (US$), 2018
  • Figure 9-15 Cisplatin - Available Concentrations (ml), 2018
  • Figure 9-16: Cisplatin - Price Analysis by Concentration (US$), 2018
  • Figure 9-17: Topotecan - Patent Approval & Expiration Year
  • Figure 9-18: Topotecan - Available Concentration by Form (mg), 2018
  • Figure 9-19: Topotecan - Dosage Analysis by Route of Administration (mg/m2/Dose), 2018
  • Figure 9-20: Topotecan - Treatment Cycle Analysis (Number of Days), 2018
  • Figure 9-21: Topotecan - Dosage Analysis by Route of Administration (mg/Cycle), 2018
  • Figure 9-22: Topotecan - Capsule Price Analysis by Concentration (US$/Unit), 2018
  • Figure 9-23: Topotecan - Price Analysis by Drug Form (US$/Packet), 2018
  • Figure 9-24: Alimta Patent Approval & Expiration Year for Advanced Lung Cancer Treatment
  • Figure 9-25: Alimta - Available Concentration (mg), 2018
  • Figure 9-26: Alimta - Dosage Analysis (mg/Day), 2018
  • Figure 9-27: Alimta - Price Analysis by Concentration (US$), 2018
  • Figure 10-1: Patent Approval & Expiry Year of Denosumab Drug
  • Figure 10-2: Denosumab - Available Concentration & Dosage Analysis by Brand (mg/Day), 2018
  • Figure 10-3: Denosumab Comparative Cost Analysis - Xgeva v/s Prolia (US$/Unit)
  • Figure 10-4: Xofigo Patent Approval & Expiry Year
  • Figure 10-5: Xofigo - Therapy Cost Analysis (US$), 2018
  • Figure 10-6: Patent Approval Year & Expiry Year
  • Figure 10-7: Zometa - Available Concentrations (mg/ml), 2018
  • Figure 10-8: Zometa - Dosage & Treatment Cycle Duration Analysis (mg/Cycle), 2018
  • Figure 10-9: Zometa - Price Analysis (US$/Vial), 2018
  • Figure 11-1: Capecitabine - Available Concentrations (mg), 2018
  • Figure 11-2: Capecitabine - Dosage Analysis (mg/m2/Day), 2018
  • Figure 11-3: Capecitabine - Treatment Cycle Duration Analysis (Number of Weeks), 2018
  • Figure 11-4: Capecitabine & Xeloda - Comparative Cost Analysis by Concentration (US$/Packet), 2018
  • Figure 11-5: Eribulin Drug Patent Approval Year & Expiration Year for Metastatic Breast Cancer
  • Figure 11-6: Eribulin - Availability & Dosage Analysis (mg), 2018
  • Figure 11-7: Eribulin - Price Analysis (US$), 2018
  • Figure 11-8: Eribulin - Clinical Efficacy Based on Clinical Trial Results (%), 2018
  • Figure 11-9: Ixabepilone Patent Approval & Expiry Year for Breast Cancer Treatment
  • Figure 11-10: Ixempra - Available Concentrations (MG), 2018
  • Figure 11-11: Ixempra - Dosage Analysis (mg/m2/Day), 2018
  • Figure 11-12: Ixempra - Price Analysis by Concentration (US$), 2018
  • Figure 11-13: Avastin Patent Approval & Expiration Year
  • Figure 11-14: Avastin - Available Concentrations (ml), 2018
  • Figure 11-15: Avastin - Average Dosage Analysis (mg/kg), 2018
  • Figure 11-16: Avastin - Price Analysis (US$), 2018
  • Figure 11-17: Avastin - Clinical Efficacy Based on Clinical Trial Results (%), 2018
  • Figure 11-18: Herceptin - Available Concentrations (mg), 2018
  • Figure 11-19: Herceptin - Dosage Analysis (mg/kg), 2018
  • Figure 11-20: Herceptin - Price Analysis by Concentration (US$), 2018
  • Figure 12-1: Nexavar - Patent Approval & Expiry Year
  • Figure 12-2: Nexavar - Availability & Dosage Analysis (mg), 2018
  • Figure 12-3: Nexavar - Price Analysis (US$), 2018
  • Figure 12-4: Nexavar - Therapy Cost Analysis (US$/Patient), 2018
  • Figure 12-5: Alkeran - Drug Patent Approval & Expiration Year
  • Figure 12-6: Alkeran - Available Concentrations by Drug Form (mg), 2018
  • Figure 12-7: Alkeran - Treatment Cycle Analysis (By Number), 2018
  • Figure 12-8: Alkeran - Price Analysis by Drug Form (US$), 2018
  • Figure 13-1: Docetaxel - Available Concentrations (mg/ml), 2018
  • Figure 13-2: Docetaxel - Dosage Analysis (mg/m2/Dose), 2018
  • Figure 13-3: Docetaxel - Price Analysis (US$/Unit), 2018
  • Figure 13-4: Jevtana - Patent Approval & Expiry Year for Metastatic Prostate Cancer Treatment
  • Figure 13-5: Jevtana - Available Concentration & Dosage Analysis (mg), 2018
  • Figure 13-6: Jevtana - Price Analysis (US$), 2018
  • Figure 13-7: Patent Approval Years of Provenge Drug in US & Europe
  • Figure 13-8: Provenge - Number of Autologous CD54+ Activated Cells (Million)
  • Figure 13-9: Provenge - Dosage Administration (Minutes)
  • Figure 13-10: Provenge - Average Duration of Therapy
  • Figure 13-11: Provenge - Cost of Intravenous Solution & per Unit Cost, US$
  • Figure 13-12: Provenge - Therapy Cost Analysis (US$/Infusion), 2018
  • Figure 13-13: Provenge - Average Cost (US$/Patient), 2018
  • Figure 13-14: Provenge - Therapy Cost Analysis (US$/Treatment Course), 2018
  • Figure 13-15: Overall Survival Rate among the Patients Using Provenge Drug (%)
  • Figure 14-1: Global - Metastatic Cancer Therapy Market Forecast (US$ Billion), 2017-2027
  • Figure 14-2: Global - Breast Cancer Therapeutics Forecast (US$ Billion), 2016-2026
  • Figure 14-3: Global - Prostate Cancer Therapeutics Market Forecast (US$ Billion), 2016-2027
  • Figure 14-4: Global - Tarceva Sales (US$ Million), 2015 - 2017
  • Figure 14-5: Global - Iressa Sales Analysis (US$ Million), 2015 - 2017
  • Figure 14-6: Global - Hycamtin Sales Analysis (US$ Million), 2015 & 2016
  • Figure 14-7: Global - Alimta Sales Analysis (US$ Million), 2015 - 2017*
  • Figure 14-8: Global - Prolia Sales Analysis (US$ Million), 2015 - 2017*
  • Figure 14-9: Global - Xofigo Sales Analysis (US$ Million), 2015 & 2017*
  • Figure 14-10: Global - Eribulin Sales Analysis (US$ Million), 2015 & 2016
  • Figure 14-11: Global - Avastin Sales Analysis (US$ Billion), 2015 - 2017*
  • Figure 14-12: Global - Herceptin Sales Analysis (US$ Billion), 2015 - 2017*
  • Figure 14-13: Global - Nexavar Sales Analysis (US$ Million), 2015 - 2017*
  • Figure 14-14: Global - Jevtana Sales Analysis (US$ Million), 2015 - 2017*
  • Figure 14-15: Global - Provenge Sales Analysis (US$ Million), 2015 & 2016
  • Figure 15-1: Favorable Parameters to Metastatic Cancer Market Growth
  • Figure 15-2: Challenges for the Development of Metastatic Cancer Treatment
  • Figure 17-1: Global Cancer Metastases Pipeline by Phase (%), 2018 till 2024
  • Figure 17-2: Global Cancer Metastases Pipeline by Phase (Number), 2018 till 2024
  • Figure 17-3: Global Cancer Metastases Pipeline by Phase (%), 2018 till 2024
  • Figure 17-4: Global Cancer Metastases Pipeline by Phase (Number), 2018 till 2024

List of Tables

  • Table 3-1: Role of Tumor Secreted Factors in Establishment of Osteolytic & Osteoblastic Metastasis
  • Table 4-1: Organ Specific Breast Cancer Metastasis Progression & Virulence
  • Table 6-1: Modern Challenges & Solutions in Management of Brain Metastasis
  • Table 9-1: Patients Benefited by Using Afatinib Drug for Metastatic Lung Cancer
  • Table 9-2: Formulation & Preparation of Topotecan Drug, mg
  • Table 11-1: Clinical Efficacy of Using Eribulin for Metastatic Breast Cancer Treatment
  • Table 11-2: Clinical Efficacy of Using Ixempra for Metastatic Breast Cancer Treatment
  • Table 11-3: Clinical Efficacy Result of Avastin Drug with Paclitaxel drug
  • Table 11-4: Clinical Efficacy for the use of Herceptin Combined with Paclitaxel or Docetaxel
Back to Top